CBD has been studied for specific canine conditions
Veterinary cannabis research includes controlled studies of CBD as an additional treatment for drug-resistant epilepsy and for osteoarthritis-related pain in dogs. These are distinct clinical problems: seizure control is measured through episodes and seizure days, while joint disease involves pain and movement.
The studies do not treat cannabis as a single therapy for every pet. They use particular preparations in animals with defined conditions, and monitor both benefit and adverse effects. This gives the treatment process a concrete structure: a diagnosis, a target outcome and a way to observe change.
Epilepsy research kept established treatment in place
A 2023 double-blind crossover study involved fifty-one dogs with drug-resistant idiopathic epilepsy. Dogs continued antiseizure medication while researchers compared additional CBD with placebo. An initial treatment condition met a futility rule after twelve dogs; the subsequent condition was studied in thirty-nine dogs.
In that later group, seizure days decreased by 24.1 percent during CBD treatment and increased by 5.8 percent during placebo. Total seizure frequency also improved. However, the number of dogs achieving at least a fifty-percent reduction did not differ significantly. A group-average improvement therefore did not mean that every dog became a major responder, and the experiment did not test replacing established medication with CBD.
Follow-up included adverse effects
In the same trial, liver-enzyme activity increased, and reduced appetite and vomiting were more common during the CBD phase. Those observations are part of the result, alongside seizure reduction. They explain why a treatment review needs more than a general impression that a dog seems calmer.
For epilepsy, the dates and frequency of episodes give the clinician a concrete record. Changes in appetite, activity or other medicines provide context. The veterinarian can then assess whether a change represents benefit, an adverse effect or an unrelated development rather than assuming that everything occurring after treatment has the same cause.
Joint-pain studies use different outcomes
A 2018 placebo-controlled crossover trial in dogs with osteoarthritis had sixteen dogs complete the study. Owner pain and activity scores improved during CBD treatment, and veterinary assessment also found reduced pain. An increase in alkaline phosphatase was observed.
This is a different therapeutic question from epilepsy. A dog getting up more easily or moving more comfortably is a relevant joint-disease outcome; it is not evidence of seizure control, nor proof that damaged joints have been repaired. Species also matters: a canine study should not be treated as a completed trial in cats or other companion animals.
A treatment process is more than choosing a product
In the epilepsy trial, seizure records showed fewer seizure days during CBD treatment, but the proportion of dogs achieving at least a 50% reduction did not differ significantly from placebo. Liver-enzyme increases, reduced appetite and vomiting were more frequent with CBD. Follow-up therefore includes seizure frequency, appetite, gastrointestinal symptoms and laboratory results alongside the animal’s established antiseizure treatment.
Sources & further reading
General information, not individual legal or medical advice.